ELAB
Price
$4.42
Change
-$0.13 (-2.86%)
Updated
Apr 3 closing price
Capitalization
2.63M
LXRX
Price
$0.43
Change
-$0.01 (-2.27%)
Updated
Apr 4, 10:47 AM (EDT)
Capitalization
160.21M
27 days until earnings call
Ad is loading...

ELAB vs LXRX

Header iconELAB vs LXRX Comparison
Open Charts ELAB vs LXRXBanner chart's image
PMGC Holdings
Price$4.42
Change-$0.13 (-2.86%)
Volume$30.04K
Capitalization2.63M
Lexicon Pharmaceuticals
Price$0.43
Change-$0.01 (-2.27%)
Volume$37.73K
Capitalization160.21M
ELAB vs LXRX Comparison Chart
Loading...
ELAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ELAB vs. LXRX commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAB is a Hold and LXRX is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (ELAB: $4.42 vs. LXRX: $0.44)
Brand notoriety: ELAB and LXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ELAB: 14% vs. LXRX: 55%
Market capitalization -- ELAB: $2.63M vs. LXRX: $160.21M
ELAB [@Biotechnology] is valued at $2.63M. LXRX’s [@Biotechnology] market capitalization is $160.21M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELAB’s FA Score shows that 1 FA rating(s) are green whileLXRX’s FA Score has 1 green FA rating(s).

  • ELAB’s FA Score: 1 green, 4 red.
  • LXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, LXRX is a better buy in the long-term than ELAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELAB’s TA Score shows that 5 TA indicator(s) are bullish while LXRX’s TA Score has 5 bullish TA indicator(s).

  • ELAB’s TA Score: 5 bullish, 3 bearish.
  • LXRX’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, LXRX is a better buy in the short-term than ELAB.

Price Growth

ELAB (@Biotechnology) experienced а -9.43% price change this week, while LXRX (@Biotechnology) price change was +27.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.89%. For the same industry, the average monthly price growth was -11.08%, and the average quarterly price growth was -14.87%.

Reported Earning Dates

LXRX is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-8.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LXRX($160M) has a higher market cap than ELAB($2.63M). LXRX YTD gains are higher at: -39.986 vs. ELAB (-72.427). ELAB has higher annual earnings (EBITDA): -4.75M vs. LXRX (-184.29M). LXRX has more cash in the bank: 238M vs. ELAB (6.43M). ELAB has less debt than LXRX: ELAB (103K) vs LXRX (108M). LXRX has higher revenues than ELAB: LXRX (31.1M) vs ELAB (2.45M).
ELABLXRXELAB / LXRX
Capitalization2.63M160M2%
EBITDA-4.75M-184.29M3%
Gain YTD-72.427-39.986181%
P/E RatioN/AN/A-
Revenue2.45M31.1M8%
Total Cash6.43M238M3%
Total Debt103K108M0%
FUNDAMENTALS RATINGS
LXRX: Fundamental Ratings
LXRX
OUTLOOK RATING
1..100
28
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
54
P/E GROWTH RATING
1..100
17
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ELABLXRX
RSI
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bullish Trend 1 day ago
50%
Bullish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 10 days ago
84%
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
ELAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DEMIX21.35N/A
N/A
Macquarie Emerging Markets Instl
SLRYX40.63N/A
N/A
SEI Large Cap Growth Y (SIMT)
GLEPX14.68N/A
N/A
GS Energy Infrastructure Fd Instl Shares
LHCVX18.45N/A
N/A
Lord Abbett Health Care R6
DREYX41.12-1.86
-4.33%
Davis Real Estate Y

ELAB and

Correlation & Price change

A.I.dvisor tells us that ELAB and EPIX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ELAB and EPIX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELAB
1D Price
Change %
ELAB100%
-2.86%
EPIX - ELAB
31%
Poorly correlated
N/A
LXRX - ELAB
25%
Poorly correlated
-11.91%
EDSA - ELAB
22%
Poorly correlated
-5.31%
ALLK - ELAB
21%
Poorly correlated
-0.40%
REGN - ELAB
20%
Poorly correlated
-2.39%
More